TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06975787: A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$3,847,440

Rescue Site Savings

+$2,533,680

Unlock Full NCT06975787 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06975787 Rescue Dossier →